Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0151
OPINION
|
Multimodal treatment including trastuzumab for gastroesophageal junction cancer: Controversy, and individualized decision.
|
Prof. Andreas Sendler, M.D., Ph.D
|
Affiliation:
Direktor der Chirurgischen Universitätsklinik, Marienhospital Herne Klinikum der Ruhr-Universität Bochum, Hölkeskampring 40, 44625, Herne, Germany.
E-mail :
Andreas.Sendler@ruhr-uni-bochum.de |
ABSTRACT
Cancer arises at the gastroesophageal junction (GEJ), namely distant esophagus (type I), cardia (type II) or proximal stomach (type III) has a poor prognosis. Surgery and chemotherapy for resectable disease are the backbone treatment. However, there is still controversy on extent of surgery, timing (preoperative, postoperative, perioperative) of chemotherapy, cytotoxic drugs regimen, radiotherapy and targeted therapy.
Here I discuss the risks and benefits of extensive surgery including thoracotomy and esophagus resection and total gastrectomy, of neoadjuvant or perioperative (before and after surgery) chemotherapy and indications and limitations of trastuzumab. Moreover, I describe how cancer whole genome sequencing and systems biology approaches may lead to novel biomarkers and drugs development with a true clinical benefit for patients with GEJ cancer.
(Citation: Gastric & Breast Cancer 2011; 10(1): 30-35)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €33 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 8 February 2011 |
|
